-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Eli Lilly announced today that the US government has purchased additional neutralizing antibody therapy authorized by it for emergency use to treat COVID-19
The recent increase in COVID-19 cases has led to a substantial increase in the utilization of monoclonal antibody drugs, especially in areas with low vaccination rates across the country
Pseudovirus and real virus studies have shown that the double antibody therapy of esvirizumab and banivirimab retains the neutralizing activity of alpha and delta mutations
It is reported that at the beginning of the outbreak in 2020, the local innovative pharmaceutical company Junshi Biotechnology and the Institute of Microbiology of the Chinese Academy of Sciences jointly developed a neutralizing antibody against the new coronavirus, esvirizumab.
At present, diabody therapy has been authorized for emergency use in 12 countries and regions including the United States and Italy
Note: The original text has been deleted